Valuation dashboard for Septerna Inc (SEPN) with P/E N/A, P/B 4.63, EV/EBITDA -41.49 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
Analysis Summary
Trailing-twelve-month margins: gross margin 99.6%, operating margin -44.0%, net margin -24.5%.
At the current price of $38.44, SEPN has negative trailing earnings (P/E not meaningful) and an ROE of -6.31%. Market capitalisation stands at $1.7B.
Balance sheet quality for SEPN: current ratio of 4.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 4.63 |
| EV / EBITDA | -41.49 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-20.37 |
| vs Current Price | -153.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SEPN | Septerna Inc | $1.7B | 4.63 | -6.3% | |
| NRIX | Nurix Therapeutics, Inc. | $2.6B | 6.67 | -76.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% |
Price
| Price | $38.44 |
| Market Cap | $1.7B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -6.31% |
| Return on Invested Capital | -8.89% |
| Return on Assets | -4.28% |
| Gross Margin | 99.57% |
| Operating Margin | -44.04% |
| Net Margin | -24.51% |
Related companies: ABUS · BCAX · EYPT · FTRE · KURA · MRVI · NRIX
Explore sector: Healthcare · Biotechnology
More sections of SEPN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks